Zanzalintinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Zanzalintinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
NDA/BLA
Highest phase
46
Registered trials
16
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Zanzalintinib can convert its Small molecule drug profile and AXL x MerTK x TYRO3 x VEGFR1 x c-Met biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Zanzalintinib (query alias: zanzalintinib) |
|---|---|
| Modality / target | Small molecule drug; AXL x MerTK x TYRO3 x VEGFR1 x c-Met; AXL inhibitors, MerTK inhibitors, TYRO3 inhibitors |
| Highest global status | NDA/BLA |
| Originator | Exelixis, Inc. |
| Active developers | Exelixis, Inc., Merck Sharp & Dohme LLC |
The MCP disease footprint includes Metastatic Colorectal Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07682675 | Phase 2 | Not yet recruiting | 51 | Efficacy of zanzalintinib in patients with recurrent and/or metastatic ACC patients in terms of Objective Response Rate (ORR) at 12 weeks |
| NCT07691476 | Phase 2 | Not yet recruiting | 48 | Overall Response Rate |
| NCT07623460 | Phase 2 | Not yet recruiting | 30 | Radiographic progression free survival (rPFS) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
LITESPARK-033: Phase 3 study of belzutifan plus zanzalintinib versus cabozantinib for recurrent clear cell renal cell carcinoma during or after adjuvant anti–PD-(L)1 therapy.
Phase 3; n=904; evaluation: Positive. Reported fields: OS = NR ; OS = NR
Contribution of atezolizumab (atezo) to the efficacy of the zanzalintinib (zanza) + atezo combination in patients (pts) with previously treated metastatic colorectal cancer (mCRC): Evidence from the phase 3 STELLAR-303 trial.
Phase 3; n=451; evaluation: Positive. Reported fields: TEAE(any-grade) = 98.0 % ; TEAE(any-grade) = 99.0 % ; TEAE(any-grade) = 98.0 %
A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy.
Phase 2; n=40; evaluation: Positive. Reported fields: TRAE(Grade ≥3) = The most common grade ≥3 adverse events were hypertension (21%, all related to study drug), hypophosphatemia (16%), and hyponatremia (14%)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Zanzalintinib addresses Metastatic Colorectal Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-10-14 | Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma | Approved | Financial terms not disclosed |
| 2021-06-14 | Exelixis and BMS collaborate on phase Ib clinical trial of XL-092 combined with immune-oncology treatments for advanced solid tumors. | Phase 1 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
